PDC and neoplasm: Although type I IFNs play a critical role in anti-tumor immune response, previous studies have reported pDC dysfunction and acquisition of tolerogenic function in the tumor bed (19–21), thus providing evidence that cancer cells do adopt immunoregulatory strategies to evade intra-tumoral activation of pDCs.